Your browser doesn't support javascript.
loading
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
Bell, R; Brown, J; Parmar, M; Toi, M; Suter, T; Steger, G G; Pivot, X; Mackey, J; Jackisch, C; Dent, R; Hall, P; Xu, N; Morales, L; Provencher, L; Hegg, R; Vanlemmens, L; Kirsch, A; Schneeweiss, A; Masuda, N; Overkamp, F; Cameron, D.
Afiliação
  • Bell R; Faculty of Medicine, Deakin University, Geelong, Australia.
  • Brown J; Clinical Trials Research Unit, University of Leeds, Leeds.
  • Parmar M; Medical Research Council Clinical Trials Unit, London, UK.
  • Toi M; Faculty of Medicine, Kyoto University, Kyoto, Japan.
  • Suter T; Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland.
  • Steger GG; Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Pivot X; Medical Oncology Service, University Hospital Jean Minjoz, Besançon, France.
  • Mackey J; Medical Oncology, Cross Center Institute, Edmonton, Canada.
  • Jackisch C; Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach, Germany.
  • Dent R; Department of Medical Oncology, National Cancer Center, Singapore, Singapore, and Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada.
  • Hall P; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Xu N; Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Morales L; Product Development Oncology, F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Provencher L; Centre des Maladies du Sein Deschênes-Fabia, CHU de Québec-Hôpital du Saint-Sacrement, Ville de Québec, Québec, Canada.
  • Hegg R; Oncology Department, Perola Byington Hospital/FMUSP, São Paulo, Brazil.
  • Vanlemmens L; Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
  • Kirsch A; Onkologischer Schwerpunktam Oskar-Helene-Heim, Berlin, Germany.
  • Schneeweiss A; Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
  • Masuda N; Department of Surgery, Breast Oncology NHO Osaka National Hospital, Osaka, Japan.
  • Overkamp F; Oncologianova, Recklinghausen, Germany.
  • Cameron D; Edinburgh University Cancer Research Centre, University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, UK.
Ann Oncol ; 28(4): 754-760, 2017 Apr 01.
Article em En | MEDLINE | ID: mdl-27993816
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Neoplasias de Mama Triplo Negativas / Bevacizumab Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Neoplasias de Mama Triplo Negativas / Bevacizumab Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália